Investment firm BMO Capital downgraded Amgen's stock from "Outperform" to "Market Perform" following a major clinical trial failure by Novartis for a similar cholesterol drug. Novartis' drug pelacarsen failed in a late-stage Phase III trial, casting uncertainty on Amgen's olpasiran, which targets the same high Lp(a) cholesterol market. Amgen shares dropped 5% after the news but have still gained 36.3% year-to-date, outperforming the industry. The downgrade signals cautious investor sentiment amid increased risks for this multi-billion dollar drug market segment.
Amgen's Phase 3 DeLLphi-305 study demonstrated that IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca's durvalumab significantly improves overall survival, progression-free survival, and response rates compared to durvalumab alone in patients wit...
Novartis announced that its drug pelacarsen, designed to lower the harmful cholesterol Lp(a), failed to significantly reduce cardiovascular events in a late-stage trial. This setback raises doubts about the effectiveness of targeting Lp(a) to prevent...
Representative David J. Taylor of Ohio reported six stock trades, selling biotech and tech shares like Amgen and Microsoft, while buying utilities, semiconductors, and regional bank stocks such as American Electric Power, Broadcom, and Fifth Third Ba...
The iShares Biotechnology ETF (IBB) surged 26% over three months ending September 4, 2026, outperforming the S&P 500's 4% gain by 22 points. This rally is driven by big pharmaceutical companies acquiring mid- and small-cap biotech firms to offset rev...
The article compares two popular U.S. retirement income ETFs: Schwab U.S. Dividend Equity ETF (SCHD) and JPMorgan Equity Premium Income ETF (JEPI). SCHD focuses on growing qualified dividends from strong American companies, offering a lower yield (~3...
